Focus: aTyr Pharma is a publicly-traded therapeutic protein company focused on respiratory and infectious disease treatments, operating as a clinical-stage biotech with minimal revenue generation.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow aTyr Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from aTyr Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for aTyr Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease - AOL.com
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease AOL.com
aTyr Pharma Jumps 5% After FDA Signs Off on Phase 3 Trial Design for Lung Disease Drug - finance.biggo.com
aTyr Pharma Jumps 5% After FDA Signs Off on Phase 3 Trial Design for Lung Disease Drug finance.biggo.com
aTyr Pharma (NASDAQ: ATYR) Initiates Phase 3 Efzofitimod Trial with 5.0 mg/kg Dosing for Pulmonary Sarcoidosis - Kalkine Media
aTyr Pharma (NASDAQ: ATYR) Initiates Phase 3 Efzofitimod Trial with 5.0 mg/kg Dosing for Pulmonary Sarcoidosis Kalkine Media
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - GlobeNewswire
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis GlobeNewswire
Layoff Tracker: Novo workforce down 13,000 - BioSpace
Layoff Tracker: Novo workforce down 13,000 BioSpace
Fierce Biotech Layoff Tracker 2026: Merck trims more NJ jobs; Novartis nixes Swiss site - Fierce Biotech
Fierce Biotech Layoff Tracker 2026: Merck trims more NJ jobs; Novartis nixes Swiss site Fierce Biotech
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Histidine Supplementation Stabilizes Hearing and Vision and Improves Growth in HARS1-Related Autosomal Recessive Disorder Associated With Usher-Like Symptoms.
Natural Asp-tRNA Synthetase Fragment Targets Myofibroblasts to Abrogate Tissue Fibrosis.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo